The immune system's ability to distinguish self from non-self is fundamental to health, but sometimes this distinction breaks down, leading to autoimmune disease. In recent years, a growing body of evidence has pointed toward a subtle and often overlooked driver of such breakdowns: the long-term persistence of viruses within the body. While acute viral infections are typically cleared within days or weeks, some viruses establish a lasting presence, hiding in tissues and periodically reactivating. This state—known as viral persistence—may continuously stimulate the immune system in ways that ultimately trigger chronic autoimmune responses. Understanding this connection is reshaping how researchers think about the origins of diseases like multiple sclerosis, lupus, and rheumatoid arthritis, and it is opening the door to novel therapeutic strategies that target not just the immune system but the viruses themselves.

What Is Viral Persistence?

Viral persistence refers to the ability of certain viruses to remain in a host organism for extended periods—often for the lifetime of the host—without being completely eliminated by the immune system. Unlike a lytic infection, in which the virus rapidly replicates and destroys host cells, persistent viruses employ strategies to evade immune clearance. They may enter a latent state where viral activity is minimal, or they may replicate at very low levels, continuously shedding viral particles. This low-grade presence can go unnoticed for years, yet it keeps the immune system on constant alert.

Classic examples of persistent viruses include the Epstein-Barr virus (EBV), which infects over 90% of the global adult population and remains latent in B cells; cytomegalovirus (CMV), a herpesvirus that persists in myeloid cells; human immunodeficiency virus (HIV), which integrates into the host genome and establishes reservoirs; and hepatitis B and C viruses, which can cause chronic liver infections. Each of these viruses has developed sophisticated mechanisms to avoid detection—such as downregulating major histocompatibility complex (MHC) molecules, producing decoy receptors, or interfering with interferon signaling. The result is a long-term host-pathogen standoff that, for most people, remains asymptomatic. But in a subset of individuals, this persistent viral presence may tilt the immune system toward self-attack.

How Persisting Viruses Evade and Manipulate the Immune System

To truly grasp the link between viral persistence and autoimmune disease, it helps to examine how these viruses survive. The immune system normally clears an infection by recognizing viral antigens through innate sensors (like Toll-like receptors) and adaptive responses (T cells and antibodies). Persistent viruses, however, possess a toolkit for subversion. For instance, EBV produces a protein called BCRF1 that mimics the human cytokine interleukin-10, dampening antiviral immune responses. CMV encodes a set of US proteins that prevent MHC class I molecules from reaching the cell surface, making infected cells invisible to cytotoxic T cells. HIV not only infects and kills CD4+ T cells but also establishes latent reservoirs in resting memory T cells, effectively hiding from antiretroviral drugs and the immune system.

These evasive tactics do more than just protect the virus. They create an environment of chronic immune activation. The presence of persistent viral antigens means that immune cells are constantly being stimulated, leading to elevated levels of pro-inflammatory cytokines such as interferon-gamma, tumor necrosis factor-alpha, and interleukin-6. This low-level inflammation, while not immediately destructive, can gradually alter the immune system's balance. Over years or decades, it may prime the immune system to misinterpret self-antigens as threats, particularly in genetically susceptible individuals.

Mechanisms Linking Viral Persistence to Autoimmunity

Several distinct but overlapping mechanisms explain how persistent viruses can trigger autoimmune responses. Understanding these pathways is essential for developing targeted therapies.

Molecular Mimicry

The most widely studied mechanism is molecular mimicry, where viral proteins share structural similarities with human proteins. When the immune system mounts a robust response against a viral epitope, cross-reactive T cells or antibodies may also attack self-tissues that bear a similar peptide sequence. A classic example involves EBV and multiple sclerosis (MS). Research has shown that the EBV nuclear antigen 1 (EBNA1) contains a sequence that mimics the human myelin basic protein. In some individuals, immune cells primed to attack EBNA1 mistakenly target myelin sheaths in the central nervous system, leading to the demyelination characteristic of MS. A landmark 2022 study published in Science provided strong epidemiological evidence that EBV infection precedes MS onset in nearly all cases, strongly supporting a causal role through molecular mimicry (Bjornevik et al., 2022).

Bystander Activation and Epitope Spreading

Persistent viruses can also cause autoimmunity through bystander activation. When a virus infects a tissue, it triggers inflammation that damages surrounding cells. This releases self-antigens that were previously hidden from the immune system. Dendritic cells can then present these self-antigens to T cells, breaking self-tolerance. Over time, the immune response may broaden through epitope spreading—where T cells initially targeting a viral epitope start to recognize additional epitopes on the same self-protein or even entirely different self-proteins. This phenomenon has been observed in animal models of type 1 diabetes, where Coxsackievirus B infection appears to accelerate pancreatic beta-cell destruction via epitope spreading (Rodriguez-Calvo et al., 2019).

Defective Viral Genomes and Immune Complex Deposition

Another less appreciated mechanism involves the accumulation of defective viral genomes during persistent infection. These are truncated or mutated viral particles that cannot replicate but still stimulate innate immune sensors, leading to chronic interferon production. Prolonged interferon exposure can upregulate MHC molecules and costimulatory signals on antigen-presenting cells, lowering the threshold for autoreactive T cell activation. Additionally, in diseases like systemic lupus erythematosus (SLE), persistent viral infections drive the production of immune complexes (antigen-antibody aggregates) that deposit in tissues such as the kidneys and joints, triggering inflammation and damage. Elevated levels of interferon-alpha—a hallmark of SLE—have been linked to chronic activation of plasmacytoid dendritic cells by viral nucleic acids, particularly from EBV and endogenous retroviruses (Crow, 2019).

Alteration of Regulatory T Cell Function

Persistent viruses may also impair the regulatory arm of the immune system. Regulatory T cells (Tregs) normally suppress autoreactive lymphocytes. Chronic viral infection, especially with HIV or CMV, has been associated with a decline in Treg numbers or function. Without adequate suppression, self-reactive clones that are kept in check under normal conditions can expand and cause tissue damage. Conversely, some viruses induce Treg expansion to benefit their own persistence, creating a double-edged sword where the host becomes more tolerant of viral antigens but also more susceptible to losing control over self-reactive cells.

Specific Autoimmune Diseases Linked to Persistent Viruses

The idea that viral persistence contributes to autoimmunity is not a one-size-fits-all hypothesis. Different viruses appear to be associated with different autoimmune conditions, and the strength of evidence varies.

Multiple Sclerosis and Epstein-Barr Virus

Perhaps the strongest link exists between EBV and multiple sclerosis. Multiple epidemiological studies have shown that nearly all MS patients are seropositive for EBV, whereas EBV-negative individuals have an extremely low risk of developing MS. The risk rises dramatically after infectious mononucleosis (symptomatic primary EBV infection). In 2022, a large prospective study of U.S. military personnel found that MS risk increased more than 30-fold after EBV infection, but not after infection with other common viruses (Bjornevik et al., 2022). This suggests that EBV is not just a risk factor but a necessary step in MS pathogenesis for most people, acting through molecular mimicry and the transformation of B cells that later become pathogenic.

Research is now exploring whether antiviral drugs against EBV or vaccines that prevent EBV infection could reduce MS incidence. Clinical trials of anti-EBV therapies in MS are underway, and early results have shown some reduction in disease activity (Magliozzi et al., 2022).

Systemic Lupus Erythematosus and Epstein-Barr Virus

Systemic lupus erythematosus (SLE) is another autoimmune disease intimately tied to EBV. SLE patients often have high antibody titers against EBV, and EBV DNA is more frequently detected in their blood and tissues. The virus infects B cells and can promote their survival and activation, driving the production of autoantibodies against nuclear antigens (like anti-dsDNA antibodies). Moreover, a subset of SLE patients shows evidence of cross-reactivity between EBV proteins and self-antigens, including the Ro/SSA and La/SSB proteins. The chronic interferon signature seen in SLE—thought to be driven by the sensing of viral nucleic acids—further links EBV persistence to disease flares (Crow, 2019).

Emerging strategies to treat SLE by targeting B cell activation (e.g., with belimumab) may indirectly reduce EBV-driven pathology. Direct antiviral approaches are also being investigated, though no EBV-specific antivirals are currently approved for SLE.

Rheumatoid Arthritis and Periodontal/Gut Viruses

Rheumatoid arthritis (RA) has a more complex viral connection. While EBV has been implicated—especially in RA patients with high titers of antibodies to EBV early antigen—there is growing interest in the role of other persistent viruses, particularly human herpesvirus 6 and porphyromonas gingivalis (a periodontal bacterium, not a virus, but often coinfectious). Additionally, the gut virome has emerged as a potential player. Changes in the composition of gut bacteriophages, which infect bacteria rather than human cells, have been linked to inflammatory arthritis. These phages may alter the bacterial community in ways that promote mucosal permeability and immune activation. The interplay between viral persistence, the microbiome, and autoimmune susceptibility is an active area of research (Mukherjee et al., 2021).

Type 1 Diabetes and Enteroviruses

Type 1 diabetes (T1D) is an autoimmune disease where the immune system destroys the insulin-producing beta cells of the pancreas. Persistent enteroviral infections, particularly with Coxsackievirus B strains, have been detected in the pancreatic islets of T1D patients. These viruses can establish low-level persistence, causing sustained inflammation and exposing beta-cell antigens. Large prospective studies like the Diabetes Autoimmunity Study in the Young (DAISY) have shown that children who develop T1D-associated autoantibodies often have prior enteroviral infections (Rodriguez-Calvo et al., 2019). Antiviral treatment with pleconaril or other drugs is being tested in early-stage T1D to see if it can preserve beta-cell function.

Therapeutic Implications: Targeting the Virus

The recognition that viral persistence may be a root cause of certain autoimmune diseases has profound implications for treatment. Current autoimmune therapies largely focus on immune suppression—reducing inflammation and blocking autoreactive cells. But such approaches are blunt instruments, often leaving patients vulnerable to infections and cancers. If a specific virus is driving disease, then antiviral strategies could offer a more targeted and perhaps curative approach.

Several avenues are being explored:

  • Antiviral drugs: Drugs that inhibit viral replication, such as acyclovir (for herpesviruses) or tenofovir (for HIV), may reduce viral load and associated immune activation. Clinical trials of valacyclovir and other anti-herpes drugs in MS are ongoing. For EBV, the drug ibrutinib (a BTK inhibitor) is being tested because it both reduces viral infection and modulates B cell signaling.
  • Therapeutic vaccines: Vaccines designed to boost T cell responses against persistent viruses—for example, an EBV vaccine targeting gp350 or a CMV vaccine—could help the immune system control viral reactivation and lower the autoimmune risk.
  • Adoptive cell therapy: Transferring virus-specific T cells (e.g., EBV-specific cytotoxic T lymphocytes) has shown promise in treating EBV-driven lymphomas and could theoretically be used to clear virus-infected cells that drive autoimmunity.
  • Immune modulation with antiviral intent: Some drugs, like interferon beta (used in MS), have both antiviral and immunomodulatory properties. Newer agents like fingolimod may indirectly reduce EBV reactivation by trapping lymphocytes in lymph nodes.

Importantly, any antiviral approach must consider the possibility that the virus is no longer needed once autoimmunity is established. In late-stage disease, the autoimmune process can become self-perpetuating, independent of the initial trigger. Therefore, early intervention at the time of first autoimmune signs may be critical.

Challenges and Future Directions

While the link between viral persistence and autoimmunity is compelling, significant challenges remain. First, proving causation is difficult. Most studies are observational and cannot distinguish whether the virus causes autoimmunity or whether autoimmunity simply makes people more susceptible to viral persistence. Prospective cohort studies that track infection prior to disease onset—like the MS/EBV study mentioned above—help, but they are expensive and time-consuming.

Second, the same virus can be associated with different autoimmune diseases in different people, and many people with persistent viruses never develop autoimmunity. This indicates that genetic susceptibility (e.g., HLA alleles like HLA-DRB1*15:01 for MS) and environmental cofactors (such as vitamin D deficiency, smoking, or gut microbiome composition) are also crucial. The virus may be a necessary but not sufficient factor.

Third, developing effective antivirals for chronic viruses like EBV or CMV has proven difficult. These viruses have co-evolved with humans for millions of years and possess redundant immune evasion mechanisms. Targeting them without harmful side effects is a major hurdle.

Looking ahead, research priorities include:

  • Identifying biomarkers that indicate which individuals with persistent viral infections are at risk of developing autoimmunity—such as specific cross-reactive antibody profiles or T cell signatures.
  • Conducting large-scale clinical trials of antiviral therapies in pre-symptomatic and early autoimmune disease.
  • Exploring the role of the virome (including bacteriophages and non-pathogenic viruses) in autoimmune regulation.
  • Developing preventive vaccines against key persistent viruses, especially EBV, for which a Phase 2 vaccine is already in trials (NCT04645147).

Conclusion

The realization that viral persistence may be a key initiator and perpetuator of chronic autoimmune responses represents a paradigm shift in immunology. It moves the focus from a purely genetic or environmental view of autoimmunity to a dynamic, host-pathogen interaction model. While much work remains to translate these insights into clinical practice, the potential is enormous. Instead of merely suppressing the immune system, future treatments may aim to remove the viral trigger, potentially halting or even reversing autoimmune disease. For millions of people living with conditions like multiple sclerosis, lupus, and type 1 diabetes, this offers a new and hopeful direction for research and therapy.